A doctor discussing treatment options with patient

GLP-1 Agonists: Exploring Their Potential in Diabetes Treatment, Obesity Management & Beyond

A thought leadership discussion about the multifaceted role of GLP-1 medications in patient care, the growing evidence for off-label uses, and the implications for health plans and their members. Glucagon-like peptide-1 (GLP-1) receptor agonists have garnered attention not only for their efficacy in diabetes care, but also for their potential in obesity management, cardiology, addiction treatment and other areas of medicine. AllMed Medical Director: Clinical Operations, Eric Diamond, DPM, DABFAS will lead a discussion with our expert panel.


  • Kathryn Kolonic, DO, MPH, CPHQ, Vice President and Regional Medical Director, ExamWorks
  • Kyle Jasper, MD, Behavioral Health Medical Director, AllMed Healthcare Management
  • Madison Forbing, PharmD, Lead Pharmacist, AllMed Healthcare Management

In this webinar you’ll learn how GLP-1 agonists (e.g., liraglutide, semaglutide, dulaglutide) work and explore their effects on glucose regulation, weight loss and cardiovascular outcomes. You’ll also hear about the emerging research suggesting applications of GLP-1 medications in the treatment of neurodegenerative disorders and addiction. Additionally, our experts will discuss the challenges facing health plans and payers regarding insurance coverage for GLP-1 agonists, including formulary placement, prior authorization and appeals processes, and strategies for crafting appropriate plan polices for patient access to these innovative therapies.


Access the webinar by completing the form below: